This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Surface-loaded nanofiber scaffolds are useful as adhesion barriers between internal organs and tissues post-surgery. Adhesion occurs during the healing process and can bring on complications such as chronic pain and reoperation failure.
== Biomolecular structure == A fibrous protein is composed of long, repetitive chains of amino acids that are intertwined to form structures resembling rods or wires. These proteins are often insoluble in water, meaning they do not dissolve. This insolubility is due to the arrangement of their amino acids; many of the amino acids that are exposed on the surface of the protein are hydrophobic (water-repelling), which causes the proteins to clump together, or aggregate, in a watery environment. A fibrous protein's peptide sequence often has limited residues with repeats; these can form unusual secondary structures, such as a collagen helix. The structures often feature cross-links between chains (e.g., cys-cys disulfide bonds between keratin chains). Fibrous proteins tend not to denature as easily as globular proteins. Miroshnikov et al. (1998) are among the researchers who have attempted to synthesize fibrous proteins.
The α-decay half-life of 240Cm was determined as 26.8 days and later revised to 30.4 days. The discovery of curium and americium in 1944 was closely related to the Manhattan Project, so the results were confidential and declassified only in 1945. Seaborg leaked the synthesis of the elements 95 and 96 on the U.S. radio show for children, the Quiz Kids, five days before the official presentation at an American Chemical Society meeting on November 11, 1945, when one listener asked if any new transuranic element beside plutonium and neptunium had been discovered during the war. The discovery of curium (242Cm and 240Cm), its production, and its compounds was later patented listing only Seaborg as the inventor.
Sources: en.wikipedia.org
=== Concentrating protein solutions === After initial purification, protein solutions may need to be concentrated to increase the protein's concentration for downstream applications. This can be achieved through various methods, including ultrafiltration, which uses semi-permeable membranes to separate proteins from smaller molecules and salts, and lyophilization (freeze-drying), which removes water and allows proteins to be stored in a stable form. Precipitation methods, such as ammonium sulfate precipitation, can also be employed to concentrate proteins by altering the solubility conditions.
== TV == Floyd on Fish, BBC TV, 1985 Floyd on Food, BBC TV, 1986 Farmhouse Kitchen, Yorkshire Television, two episodes, 1989 and 1990 Taste of the Sea, BBC TV, 1995. 6 episodes – Glenfiddich TV Programme of the Year Award, Good Food Award Television Cookery Programme of the Year Fruits of the Sea, BBC TV, 1997. 8 episodes – Silver Medal World Food Media Awards Adelaide 1997 Great Railway Journeys, BBC TV, 1999 (Los Mochis to Veracruz) Rick Stein's Seafood Odyssey, BBC TV, 1999. 8 episodes – Bronze Medal World Food Media Awards Adelaide 1999 Fresh Food, BBC TV, 1999. 6 episodes Personal Passions, BBC TV, 1999 Food and Drink, BBC TV, 1999 – Gold Award for Best Television Food Segment Within a Show: World Food Media Awards Adelaide 1999 Rick Stein's Seafood Lovers' Guide, BBC TV, 2000. 8 episodes – Glenfiddich TV Programme of the Year Award 2001 Jacob's Creek World Food Media Awards: Silver for best Television Food Show Friends for Dinner, BBC TV, 2000 Rick Stein on Fishing, ITV, 2001 Rick Stein's Food Heroes, BBC TV, 2002. 10 episodes – Jacob's Creek World Food Media Awards 2003: Gold for Best Television Food Show Rick Stein's Food Heroes, Another Helping, Series 1, BBC TV, October 2003. 6 episodes Rick Stein's Food Heroes, Another Helping, Series 2, BBC TV, February 2004. 8 episodes Rick Stein's Fish Love, UKTV Fish, August 2004 Rick Stein's French Odyssey, BBC TV, May 2005. 10 episodes Cabin Fever (Behind the scenes and the making of Rick Stein's French Odyssey), BBC TV, Autumn 2005. single 1-hour programme.
Spelt (Triticum spelta), also known as dinkel wheat, is a species of wheat. It is a relict crop, eaten in Central Europe and northern Spain. It is high in protein. In Australia it is marketed as a health food. Spelt was cultivated from the Neolithic period onward. It was a staple food in parts of Europe from the Bronze Age to the Middle Ages. It is used in baking, and is made into bread, pasta, and beer. It is sometimes considered a subspecies of the closely related common wheat (T. aestivum), with the botanical name Triticum aestivum subsp. spelta. It is a hexaploid, most likely a hybrid of wheat and emmer.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.